Dr. Daniel A. King

Daniel King, MD PhD, is a gastrointestinal medical oncologist based at the Monter Cancer Center and Director of Research and Development for the Northwell Health Cancer Institute's Center for Genomic Medicine. As an academic oncologist and active researcher, he aims to deliver the latest advances uncovered through clinical trials, breakthrough technologies, and targeted therapies, to his patients. Prior to completing medical school, he pursued scientific investigation aimed at uncovering the underpinnings of cancer. These experiences included a fellowship as a Howard Hughes Research Scholar at the National Institutes of Health and as a PhD student at the Wellcome Sanger Genomic Institute at the University of Cambridge, UK, where he studied genomics and bioinformatics. More recently, Dr. King trained in medical oncology at Stanford University where he conducted translational research in pancreatic cancer and has published in peer reviewed journals. At Northwell, in addition to his active medical practice, he conducts clinical research in partnership with Cold Spring Harbor Laboratory, where he is a clinical scholar in the laboratory of Dr. Dave Tuveson. Dr. King is board certified in Internal Medicine and Medical Oncology and is an active member of the American Association of Cancer Research.

Dr. King is rated as an Experienced provider by MediFind in the treatment of Gallbladder Cancer. His top areas of expertise are Pancreatic Cancer, Familial Pancreatic Cancer, Ampullary Cancer, Pancreaticoduodenectomy, and Pancreatectomy.

His clinical research consists of co-authoring 30 peer reviewed articles. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 30 articles in the study of Gallbladder Cancer.